Cagrilintide Dosing & Reconstitution Guide
Dosing Protocol
Route: Subcutaneous Frequency: Once weekly Dose Range: Monotherapy: 1.2-4.5 mg weekly; CagriSema: fixed dose 2.4 mg cagrilintide + 2.4 mg semaglutide Cycle Length: Ongoing for weight management Timing: Same day each week, any time
Titration Schedule
Weeks 1-4: 0.25 mg semaglutide + cagrilintide (CagriSema titration) Weeks 5-16: Gradual escalation to full dose Weeks 17+: 2.4 mg + 2.4 mg maintenance
Storage
Lyophilized: N/A (pre-filled pen anticipated) Reconstituted: 2-8 °C before first use Shelf Life: 28 days
Injection Sites
Abdomen, Thigh, Upper arm
Safety & Contraindications
Safety: GI adverse events: 79.6% in CagriSema group vs 39.9% placebo (nausea, vomiting, diarrhea, constipation) GI events mainly transient and mild-to-moderate Similar safety profile to GLP-1 class: pancreatitis risk, gallbladder events, thyroid C-cell tumors in rodents
Contraindications: Not yet established (investigational); Likely similar to GLP-1 class: personal/family history of MTC, MEN2; Pregnancy
Related Research News
Cagrilintide-Semaglutide May Aid Type 2 Diabetes Glycemic Control
A combination of cagrilintide and semaglutide could improve glycemic control in patients with type 2 diabetes who are already using basal insulin, according to a report from Docwire News. The finding suggests a potential new treatment option for managing blood sugar levels in this patient population.
Amylins (IAPP): Structure, Receptors, and Key Analogues
Amylin, or islet amyloid polypeptide (IAPP), is a 37-amino-acid peptide co-produced with insulin in pancreatic β-cells at ratios from 1:10 to 1:100. It slows gastric emptying, suppresses glucagon secretion after meals, and promotes satiety through brainstem pathways. Synthetic versions like pramlintide and cagrilintide show promise in managing postprandial glucose and obesity, with clinical trials demonstrating significant weight loss.